Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.79 USD

38.79
1,707,301

-0.37 (-0.95%)

Updated Jul 15, 2024 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Announces Data on Combination Therapy for HIV

Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

    Lilly's Olumiant Gets Marketing Authorization in Europe

    Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

      Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View

      GlaxoSmithKline plc (GSK)'s fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair.

        Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

        Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

          Mark Vickery headshot

          Strong Q4 Earnings Ahead of the Bell: TWX, GSK, ALK

          A slew of new Q4 earnings reports hit the tape this morning, covering a wide range of industries from pharma to airlines to media.

            Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y

            Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.

              Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

              Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

                GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1

                GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.

                  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

                  How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?

                    Merck???s Keytruda Gets Priority Review for Bladder Cancer

                    Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

                      GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

                      GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

                        Merck Keytruda Gets EU Approval for First-Line Lung Cancer

                        Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

                          Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

                          Value investing is easily one of the most popular ways to find great stocks in any market environment.

                            Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

                            Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

                              Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

                              Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

                                4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

                                Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

                                  Merck (MRK) Does Well in 2016: Reasons for Outperformance

                                  Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.

                                    Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

                                    Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

                                      Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

                                      Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                                        Big Pharma Face Off: Is Merck More Attractive than J&J?

                                        Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                                          Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                                          Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                                            The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                                            The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                                              Tracey Ryniec headshot

                                              Is Brexit a Buying Opportunity?

                                              Value investors should keep an eye on what is going on in Great Britain right now.

                                                Mark Vickery headshot

                                                Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others

                                                After a busy session after the bell yesterday, including strength from Apple, we see another long list of reporting companies this morning.

                                                  Brian Bolan headshot

                                                  CDXS and LOGI are Aggressive Growth Stocks

                                                  Biotech supply chain and computer peripherals are the focus